SCHEMBL6074522

SCHEMBL6074522

COc1ccc2c(c1)CCS(=O)(=O)N2C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
DRD1 P21728 7/20 0.47
DRD5 P21918 7/20 0.47
DRD2 P14416 6/20 0.47
DRD3 P35462 6/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
CA2 P00918 1/20 0.47
CA5A P35218 1/20 0.47
HSD17B10 Q99714 1/20 0.46
SRD5A1 P18405 1/20 0.44
DRD4 P21917 4/20 0.43
PKM P14618 1/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26029593 0.81 HRH3 (0.42) CA2CA5AHSD17B10KMT2AKDM4E
SCHEMBL25315075 0.80 HRH3 (0.39) DRD3KDM4E
SCHEMBL25920201 0.80 HRH3 (0.39) DRD3KDM4E
SCHEMBL26029588 0.78 TP53 (0.40) MEN1KMT2A
SCHEMBL25314670 0.78 DRD2 (0.45) DRD1DRD5DRD2DRD3CA2
SCHEMBL18756604 0.73 PER2 (0.46) NOTUMDRD1DRD5DRD2DRD3
SCHEMBL2625807 0.71 NOTUM (0.59) NOTUMDRD1DRD5DRD2DRD3
SCHEMBL6073478 0.71 TRIM24 (0.64) NOTUMDRD1DRD5DRD2DRD3
SCHEMBL31568280 0.71 LMNA (0.41) KDM4E
SCHEMBL24559113 0.70 KMT2A (0.43) MEN1KMT2AKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
US-7119207-B2 Benzoamide piperidine containing compounds and related compounds PFIZER INC (US) 2006-10-10 US disclosed
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds PFIZER INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR NOTUM 2955/4885DRD1 3193/4885DRD5 4325/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR NOTUM 2955/4885DRD1 3193/4885DRD5 4325/4885
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds TACR1, VIPR1, VIPR2 NOTUM 4111/4885DRD1 832/4885DRD5 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.